<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Thu, 05 Feb 2026 06:46:55 +0000</lastBuildDate>
    <item>
      <title>#1 [85/100] Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41609753/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41609753/</guid>
      <dc:creator>Huang Y, Sun D, Zhou H, Zhou T, Qu S, Li J, Hu C, Xu M, Li W, Shen L, et al.</dc:creator>
      <pubDate>Thu, 29 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚≠ê HIGH IMPACT - Score: 85/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This secondary analysis of a phase 3 randomized clinical trial published in JAMA Oncology evaluates the long-term survival benefits of a novel combination therapy for recurrent or metastatic nasopharyngeal carcinoma, which has significant implications for treatment guidelines.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Huang Y, Sun D, Zhou H, Zhou T, Qu S, Li J, Hu C, Xu M, Li W, Shen L, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; JAMA oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1001/jamaoncol.2025.6245'&gt;10.1001/jamaoncol.2025.6245&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-29&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41609753/'&gt;41609753&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;IMPORTANCE: Programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 inhibitors plus chemotherapy is the current standard first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). However, the long-term survival benefits at the 5-year benchmark remain uncertain. OBJECTIVE: To determine whether adding camrelizumab to chemotherapy significantly improved 5-year overall survival (OS) as first-line treatment for RM-NPC, compared with chemotherapy alone. DESIGN, SETTING, AND PARTICIPANTS: The CAPTAIN-1st trial was a randomized, double-blind, phase 3 trial conducted at 28 hospitals in China. Between November 13, 2018, and November 29, 2019, patients with treatment-naive RM-NPC were enrolled. This secondary analysis of the CAPTAIN-1st trial was prespecified. Data analysis was conducted on June 1, 2025. INTERVENTIONS: Patients were randomized (1:1) to receive camrelizumab or placebo in combination with gemcitabine and cisplatin for 4 to 6 cycles, followed by maintenance therapy with camrelizumab or placebo until disease progression, unacceptable toxic effects, or completion of 2 years of treatment. MAIN OUTCOME: The primary end point, progression-free survival per independent review committee, has been reported previously. Herein, the secondary end point of OS is reported as prespecified in the protocol. RESULTS: Among 263 randomized patients (134 in randomized to camrelizumab, 129 to placebo), baseline characteristics were generally balanced between groups, except for age. The mean (SD) age was 49 (11.25) years, and 218 patients (82.9%) were male individuals, 45 (17.1%) were female individuals. With a median survival follow-up of 63.5 (95% CI, 61.2-64.6) months for the camrelizumab group and 63.0 (95% CI, 60.8-64.6) months for the placebo group, 85 (63.4%) and 95 (73.6%) deaths occurred, respectively. Median OS was 34.5 months (95% CI, 29.4-45.7) with camrelizumab vs 26.6 months (95% CI, 19.8-33.5) with placebo (hazard ratio [HR], 0.74; 95% CI, 0.55-0.99; 2-sided P‚Äâ=‚Äâ.047). After adjusting for age imbalance, the HR was 0.65 (95% CI, 0.48-0.89; P‚Äâ=‚Äâ.01). The 5-year OS rates were 37.8% vs 24.2%, reflecting an absolute difference of 13.6% (95% CI, 2.4%-24.8%; P‚Äâ=‚Äâ.02) in favor of camrelizumab. The OS benefits were generally consistent across subgroups. In the camrelizumab group, patients who achieved rapid clearance of Epstein-Barr virus (EBV) DNA had significantly longer OS compared with those without EBV DNA clearance (HR, 0.32; 95% CI, 0.18-0.58; P‚Äâ&lt;‚Äâ.001). CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, the addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of RM-NPC. These findings provided the first 5-year evidence supporting the benefit of PD-1-based chemoimmunotherapy in this setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03707509.</description>
    </item>
    <item>
      <title>#2 [75/100] The prognostic significance of the 'Worst Pattern of Invasion' in oral cancers-an international collaborative multicentre analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41638055/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41638055/</guid>
      <dc:creator>Roy P, Weber MB, Gupta R, Kakkar A, Fonseca D, Bal M, Kamboj M, Anand N, Anila KR, Velusamy S, et al.</dc:creator>
      <pubDate>Tue, 03 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This multicenter analysis of 1374 patients provides important insights into the prognostic significance of the worst pattern of invasion in oral squamous cell carcinoma, potentially influencing clinical practice and treatment guidelines.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Roy P, Weber MB, Gupta R, Kakkar A, Fonseca D, Bal M, Kamboj M, Anand N, Anila KR, Velusamy S, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2026.107874'&gt;10.1016/j.oraloncology.2026.107874&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-03&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41638055/'&gt;41638055&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Worst pattern of invasion (WPOI) has been evaluated in many single-institute cohorts. Our goal was to perform a large multicentre evaluation of WPOI as a prognostic marker in oral squamous cell carcinoma (OSCC). Retrospective pathology data was collated from 14 institutions and compared with clinical outcome in 1374 OSCC patients with upfront curative resection. Most cases were of oral tongue (n¬†=¬†645, 47%); T2 (33%) and N0 (59%). WPOI 1-3 frequency was 29.4%, WPOI 4 47% and WPOI 5 22%. On univariable analysis, the 3-year disease free survival (DFS) was 54.2% for WPOI 5 vs. 69.7% for WPOI 1-4 (p¬†&lt;¬†0.001). The locoregional control (LRC) was 68.9% vs 79.2% (p¬†=¬†0.001), and overall survival (OS) 68.4% vs 83.8% (p¬†&lt;¬†0.001). On multivariable Cox-regression in the entire cohort, WPOI 4 or 5 was strongly correlated with other known poor prognostic factors and not an independent predictor of OS (HR 1.10, 95% CI 0.92-1.52), LRC or DFS. However, in early-stage (pT1-2¬†N0) patients treated with surgery alone without adjuvant radiotherapy, WPOI 5 was a robust independent predictor of DFS (HR 4.36, 95% CI 1.54-12.32, p¬†=¬†0.006), OS (HR 3.69, 95% CI 1.23-11.1, p¬†=¬†0.020) and LRC (HR 3.52, 95% CI 2.13-5.82, p &lt;0.001) after applying inverse probability weighting to correct for selection bias. Furthermore, in the entire cohort of early-stage patients, interaction modeling showed that adjuvant radiotherapy significantly reduces the risk for both DFS and LRC for those with WPOI-5 (Interaction p¬†=¬†0.002). Therefore, it may act as a predictive biomarker for the benefit of adjuvant radiotherapy. The prognostic and predictive role of WPOI-5 should be validated in prospective trials.</description>
    </item>
    <item>
      <title>#3 [75/100] The impact of drains on surgical outcomes in thyroid surgery-a meta-analysis of randomised controlled trials.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41622270/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41622270/</guid>
      <dc:creator>Al-Taie DS, Mughal Z, Lotfallah A, Fussey J, Deutsch P, Warner G, Daultrey CR, Ayshford C, Gupta KK</dc:creator>
      <pubDate>Sun, 01 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This meta-analysis of randomized controlled trials addresses an important clinical question regarding the use of surgical drains in thyroid surgery, potentially influencing surgical practice, although it is published in a specialty journal rather than a top-tier one.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Al-Taie DS, Mughal Z, Lotfallah A, Fussey J, Deutsch P, Warner G, Daultrey CR, Ayshford C, Gupta KK&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1007/s00405-026-10015-3'&gt;10.1007/s00405-026-10015-3&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-01&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41622270/'&gt;41622270&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;IMPORTANCE: Thyroidectomy is a commonly performed procedure with potential complications such as haematoma and seroma, which can result in life-threatening airway obstruction. Surgical drains have traditionally been used to mitigate these risks, but their necessity is increasingly debated due to concerns over pain, infection, and prolonged hospitalisation. OBJECTIVE: To evaluate the benefits and risks of using surgical drains following thyroidectomy. This meta-analysis of randomised controlled trials aimed to compare postoperative surgical outcomes in adult patients undergoing thyroid surgery, managed with or without drains. DATA SOURCES: Five electronic databases (PubMed, EMBASE, Ovid Medline, EMCARE, and CINAHL) were systematically searched in August 2025 for articles published between January 1995 and August 2025. STUDY SELECTION: Randomised controlled trials (RCTs) comparing outcomes in patients undergoing thyroidectomy with and without drains were included. Of the initial 119 articles identified, 10 RCTs were included in the final analysis, representing 1,078 patients. DATA EXTRACTION AND SYNTHESIS: Pooled proportions were calculated and transformed using the Freeman-Tukey double arcsine method. The random-effects meta-analysis of proportions was then conducted using inverse variance weighting, with between-study variance (œÑ2) estimated via the DerSimonian and Laird¬†method. MAIN OUTCOMES AND MEASURES: Primary outcomes included haematoma and seroma rates; secondary outcomes were surgical site infection (SSI), return-to-theatre (RTT), postoperative pain, and length of stay (LOS). RESULTS: Pooled complication rates were: haematoma 1.6%, seroma 3.7%, SSI 2.5%, and RTT 0.2%. Drain use was not associated with significant differences in haematoma (p‚Äâ=‚Äâ0.15), seroma (p‚Äâ=‚Äâ0.64), or RTT (p‚Äâ=‚Äâ0.22). However, SSI (4.2% vs. 0.5%, p‚Äâ=‚Äâ0.01), LOS (mean difference [MD]‚Äâ=‚Äâ1.2¬†days; p‚Äâ&lt;‚Äâ0.0001), and pain (MD‚Äâ=‚Äâ2.2; p‚Äâ=‚Äâ0.001) were significantly higher in the drain group. CONCLUSIONS AND RELEVANCE: Routine placement of drains after all types of thyroidectomies does not significantly decrease the rates of haematoma, seroma, or recurrent laryngeal nerve injury, and is linked to higher rates of surgical site infection, pain, and length of stay. A selective, patient-specific approach to drain use is recommended.</description>
    </item>
    <item>
      <title>#4 [75/100] Safety and Efficacy of Endoscopic Thyroidectomy by Gasless Unilateral Axillary for Papillary Thyroid Carcinoma in Primary Hospitals.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41612971/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41612971/</guid>
      <dc:creator>Wu K, Wei X, Lu M, Wei X</dc:creator>
      <pubDate>Fri, 30 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a prospective, single-center randomized controlled trial comparing a novel surgical technique for papillary thyroid carcinoma, which could have significant implications for surgical practice, although the sample size is moderate and the study is limited to a single institution.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Wu K, Wei X, Lu M, Wei X&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70187'&gt;10.1002/hed.70187&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-30&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41612971/'&gt;41612971&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To compare the safety and surgical efficacy of endoscopic thyroidectomy by gasless unilateral axillary (ETGUA) with conventional open thyroidectomy in patients with papillary thyroid carcinoma (PTC). METHODS: This prospective, single-center, and randomized controlled trial included 196 patients with PTC who met the inclusion and exclusion criteria. Patients were randomly assigned in a 1:1 ratio to the ETGUA group (n‚Äâ=‚Äâ98) or the open thyroidectomy group (n‚Äâ=‚Äâ98). Complications within 30‚Äâdays, parathyroid function [intact parathyroid hormone (iPTH) and serum calcium], and short-term oncological outcomes were observed. Secondary outcomes included operative time, intraoperative blood loss, postoperative recovery, pain score, cosmetic satisfaction, and hospitalization cost. RESULTS: The ETGUA group had a significantly longer operative time than the open thyroidectomy group, less intraoperative blood loss, more postoperative drainage at postoperative day 1, as well as a shorter postoperative hospital stay (all p‚Äâ&lt;‚Äâ0.05). At 1‚Äâyear postoperatively, surgical efficacy and oncological indicators such as the number of lymph nodes dissected, number of positive lymph nodes, stimulated thyroglobulin (sTg) level, and the proportion of patients receiving adjuvant radioactive iodine therapy were comparable between groups (p‚Äâ&gt;‚Äâ0.05). The ETGUA group reported lower visual analog scale (VAS) pain scores and higher cosmetic satisfaction, though the total hospitalization cost was slightly higher (all p‚Äâ&lt;‚Äâ0.05). The learning curve analysis indicated that operative time and intraoperative blood loss stabilized after approximately 30-40 cases. CONCLUSION: ETGUA demonstrates comparable safety and oncological efficacy to conventional open thyroidectomy in PTC patients.</description>
    </item>
    <item>
      <title>#5 [70/100] Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41616773/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41616773/</guid>
      <dc:creator>Haist M, Baertsch MA, Reticker-Flynn NE, Lu G, Kempchen TN, Chu P, Vazquez G, Chen H, Sunwoo JB, Zhang W, et al.</dc:creator>
      <pubDate>Thu, 29 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The study presents novel insights into the immunosuppressive mechanisms associated with lymph node colonization in head and neck cancer, utilizing advanced methodologies like spatial proteomics and transcriptomics, which could have significant clinical implications.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Haist M, Baertsch MA, Reticker-Flynn NE, Lu G, Kempchen TN, Chu P, Vazquez G, Chen H, Sunwoo JB, Zhang W, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Cancer cell | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.ccell.2026.01.003'&gt;10.1016/j.ccell.2026.01.003&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-29&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41616773/'&gt;41616773&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Lymph node (LN) colonization in cancer is linked to poor prognosis. Evidence suggests that LN colonization induces systemic immunosuppression, facilitating distant metastasis. We investigated LN-mediated immunosuppression in patients with head-and-neck cancer using spatial proteomics, spatial transcriptomics, and an in vivo model of melanoma LN metastasis. Both primary tumors and paired LNs of nodal-positive patients exhibit enhanced interferon-Œ≥ signaling and an enrichment of immunosuppressive myeloid cells and cancer-associated fibroblasts (CAFs). The spatial intersection of these myeloid-CAF-enriched niches with perifollicular T cell zones and LN follicles is linked to enhanced T cell dysfunction and Treg activation therein, thereby driving architectural LN remodeling. These immune suppressive changes extend to adjacent non-tumor-involved LN regions and nearby tumor-free LNs, but were not detected in LNs of non-cancer patients, reflecting a systemic effect that compromises anti-tumor immunity beyond the tumor-involved LN. Hence, our findings establish LN colonization as an active driver of systemic immunosuppression, facilitating metastatic progression.</description>
    </item>
    <item>
      <title>#6 [65/100] Choice and Death: Analysis of Medical Assistance in Dying for Head and Neck Cancer in Ontario.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41636338/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41636338/</guid>
      <dc:creator>Curry T, Wener E, Odell M, Caulley L, Ramchandani R, Grant A, Thavorn K, Lasso A, Kilty S</dc:creator>
      <pubDate>Wed, 04 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study provides important insights into the uptake of Medical Assistance in Dying for head and neck cancer patients, addressing a significant clinical question, but it is a retrospective analysis with a moderate sample size and does not present novel therapeutic findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Curry T, Wener E, Odell M, Caulley L, Ramchandani R, Grant A, Thavorn K, Lasso A, Kilty S&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; The Laryngoscope | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/lary.70410'&gt;10.1002/lary.70410&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-04&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41636338/'&gt;41636338&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: There is a paucity of information on the uptake of Medical Assistance in Dying (MAiD) for patients with head and neck cancer (HNC). Our study reports the prevalence, disease characteristics, and nature of the desire for MAiD in patients with HNC who underwent the process in Ontario. The aim is to better understand this population and identify gaps in our current system of care. METHODS: This is a retrospective cross-sectional analysis for the period June 17, 2016 to December 31, 2022. Data were received from the Office of the Chief Coroner Ontario, Canada. RESULTS: Three hundred and fifty-six persons received MAiD. The average age was 72.4‚Äâyears (SD 12.22) with 260 of the patients being men (73.03%). The most common HNC primary tumor site was the oral cavity 109 (30.6%). The most reported reason was inadequate control of symptoms other than pain (79.21%) followed by inadequate pain control or concerns about it (75%). The patient's private residence (55.62%) was the most common setting. Patients were more likely to live in wealthier neighborhoods and in large urban centers. Future prediction of MAiD uptake shows a linear year-by-year increase. CONCLUSION: The use of MAiD in HNC has been steadily increasing since its legalization and is projected to continue increasing. There is a male predominance that is aligned with the incidence and prevalence of HNC nationally. Overall, MAiD is an increasingly employed choice for HNC patients receiving treatment for disease without curative intent.</description>
    </item>
    <item>
      <title>#7 [65/100] Role of nutritional (PNI, CONUT) and inflammatory indices (SII) in predicting lymph node metastasis and prognosis of thyroid cancer: a systematic review and meta-analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41634408/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41634408/</guid>
      <dc:creator>Liu Y, Xiao R</dc:creator>
      <pubDate>Tue, 03 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis synthesizes data from multiple studies on nutritional and inflammatory indices in thyroid cancer, providing important insights into prognostic factors, though it does not present new clinical trials or practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Liu Y, Xiao R&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1007/s00405-025-09976-8'&gt;10.1007/s00405-025-09976-8&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-03&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41634408/'&gt;41634408&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Markers reflecting systemic inflammation and nutritional condition are now often applied in predicting cancer outcomes, yet their role in thyroid malignancies has not been clearly established. We reviewed the evidence in the literature on the role of Prognostic Nutritional Index (PNI), Controlling Nutritional Status Score (CONUT), and Systemic Immune-Inflammation Index (SII) in predicting lymph node metastasis (LNM), overall survival (OS), and disease-free survival (DFS) in thyroid cancer. METHODS: Two reviewers searched CENTRAL, Embase, PubMed, and Scopus databases till 24th August 2025 for relevant publications. A random-effects meta-analysis was conducted. RESULTS: Thirteen studies were eligible. Combined results demonstrated that elevated SII was slightly but significantly correlated with increased risk of LNM (HR: 1.00; 95% CI: 1.00-1.01; I¬≤ = 93%). Results failed to change in the sensitivity analysis. Subgroup analysis based on location and histology indicated non-significant results while meta-regression did not identify any significant moderators. Pooled analysis indicated no significant association between low PNI and DFS (HR: 1.45 95% CI: 0.97, 2.18 I2‚Äâ=‚Äâ80%) and LNM (HR: 1.31 95% CI: 0.89, 1.92 I2‚Äâ=‚Äâ73%) in thyroid cancer patients. Meta-analysis also showed that high CONUT was associated with a tendency of worse DFS in thyroid cancer, but results were non-significant (HR: 3.25 95% CI: 0.99, 10.69 I2‚Äâ=‚Äâ86%). However, meta-analysis showed that high CONUT was significantly associated with worse OS (HR: 9.67 95% CI: 1.90, 49.25 I2‚Äâ=‚Äâ61%). CONCLUSIONS: Limited data suggest that high SII may be marginally associated with increased risk of LNM in thyroid cancer, the clinical significance of which is questionable. PNI was not found to be associated with LNM or DFS in thyroid cancer patients. High CONUT was associated with poor OS and a non-significant tendency for worse DFS in thyroid cancer.</description>
    </item>
    <item>
      <title>#8 [65/100] The value of nasopharyngeal brush versus plasma EBV DNA detection in diagnosing local recurrence of nasopharyngeal carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41631491/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41631491/</guid>
      <dc:creator>Ouyang YF, Liang JL, Xie RQ, Liu YP, You R, Xia TL, Chen MY</dc:creator>
      <pubDate>Tue, 03 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study evaluates a novel diagnostic approach for detecting local recurrence of nasopharyngeal carcinoma using EBV DNA, with a moderate sample size of 187 patients. While it addresses an important clinical question and has potential implications for surveillance methods, it lacks the robustness of larger prospective studies or randomized controlled trials.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ouyang YF, Liang JL, Xie RQ, Liu YP, You R, Xia TL, Chen MY&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; International journal of cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/ijc.70357'&gt;10.1002/ijc.70357&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-03&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41631491/'&gt;41631491&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Nasopharyngeal carcinoma (NPC) remains a major challenge due to the high incidence of recurrence, often leading to therapeutic failure. Early detection of recurrence is critical, yet effective surveillance methods are limited. This study aims to evaluate the utility of Epstein-Barr virus (EBV) DNA detection in nasopharyngeal brush samples for identifying recurrent NPC. A total of 187 NPC patients who had undergone radical radiotherapy with or without chemotherapy were included. EBV DNA levels in both nasopharyngeal brush and plasma samples were analyzed using real-time quantitative PCR. Head and neck MRI, sinus endoscopy examination, and biopsy of suspicious lesions were used as the gold standard to confirm recurrence. Patients without recurrence after more than 1‚Äâyear of follow-up served as controls. Nasopharyngeal brush EBV DNA detection demonstrated significantly higher sensitivity (95.7%) for detecting recurrence compared to plasma EBV DNA testing (61.4%), with comparable specificity (94.0% vs. 96.6%). The positive predictive value was similar between methods, whereas the negative predictive value was markedly higher for the nasopharyngeal brush group (97.3% vs. 80.7%). These findings suggest that EBV DNA detection in nasopharyngeal brush samples is a highly sensitive and minimally invasive supplementary tool for monitoring NPC recurrence. This approach offers superior sensitivity and an improved negative predictive value compared to plasma EBV DNA testing, and may enhance early surveillance and clinical management of NPC recurrence.</description>
    </item>
    <item>
      <title>#9 [65/100] Salvage of locoregionally recurrent head and neck cancer: an NRG oncology working group review.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41629764/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41629764/</guid>
      <dc:creator>Ward MC, Kang JJ, Saba NF, Campbell SR, Akhave NS, Chang SS, Spencer SA, Spreafico A, Hanna GJ, Yom SS, et al.</dc:creator>
      <pubDate>Mon, 02 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This paper presents a review from a cooperative group addressing a significant clinical challenge in managing recurrent head and neck cancer, highlighting the need for further investigation, but it lacks original data or novel findings that would elevate its impact.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ward MC, Kang JJ, Saba NF, Campbell SR, Akhave NS, Chang SS, Spencer SA, Spreafico A, Hanna GJ, Yom SS, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Journal of the National Cancer Institute | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1093/jnci/djag025'&gt;10.1093/jnci/djag025&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-02&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41629764/'&gt;41629764&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Despite decades of progress in the treatment of head and neck cancer, recurrence and second primary cancers continue to occur. The management of non-metastatic, locoregionally recurrent or second primary cancers is a complex multidisciplinary challenge that often occurs without guidance from robust clinical trials. In 2023, the NRG Oncology cooperative group created the Recurrent and Metastatic Working Group with the express directive to investigate how resources could optimally address the key questions for the recurrent and metastatic populations. Here, we present our view of the state of the science and present considerations for future investigations.</description>
    </item>
    <item>
      <title>#10 [65/100] Driving progress in recurrent and metastatic head and neck cancer: the NRG oncology perspective.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41627880/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41627880/</guid>
      <dc:creator>Herrera M, Ward M, Hanna GJ, Yom SS, Heron D, Spreafico A</dc:creator>
      <pubDate>Mon, 02 Feb 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This white paper identifies critical gaps in the management of recurrent and metastatic head and neck cancer and proposes actionable recommendations, which may influence future research directions; however, it lacks primary data or novel therapeutic findings that would elevate its impact.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Herrera M, Ward M, Hanna GJ, Yom SS, Heron D, Spreafico A&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Journal of the National Cancer Institute | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1093/jnci/djag026'&gt;10.1093/jnci/djag026&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Feb-02&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41627880/'&gt;41627880&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Head and neck cancers represent a diverse group of malignancies with significant heterogeneity in biology and prognosis, for which management of advanced-stage disease remains a formidable challenge. While the incorporation of immune checkpoint inhibitors has led the way to a new era of treatment possibilities, the current state-of-the-science calls for further innovation and a nuanced approach to clinical trial design to address a number of unmet needs. This white paper from the NRG Oncology Recurrent/Metastatic Head and Neck Working Group aims to critically identify gaps in clinical practice and the scientific literature and to propose actionable recommendations for future research in the framework of recurrent/metastatic squamous cell carcinoma of the head and neck.</description>
    </item>
  </channel>
</rss>
